Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN®ST. LOUIS, March 04, 2025 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded partnership with Eton Pharmaceuticals (“Eton”), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. As part of this expanded collaboration, Optime Care will serve as the specialty pharmacy provider of a third product for Eton, dispensing the newly acquired GALZIN® (zinc acetate), an FDA-approved product used in the treatment of the ultra-rare metabolic condition of Wilson Disease.
AscellaHealth Supports Rare Disease Patients and Caregivers in Observance of Rare Disease Day, February 28BERWYN, Pa., Feb. 26, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, reaffirms its commitment to supporting the 300 million individuals worldwide affected by rare diseases. In recognition of Rare Disease Day, held annually on the last day of February, the AscellaHealth team participates in this global initiative to raise awareness about rare diseases and highlight the strength and unity within these communities. Emphasizing the need for equitable access to care, AscellaHealth acknowledges that over 6,000 rare diseases are known, 72% of which are genetic, and 70% of genetic rare diseases begin in childhood.
AscellaHealth Ranked Number 154 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™Attributes 753% Revenue Growth to Advancing Innovative Solutions for Life Sciences, Healthcare Organizations, Payers and Patients
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces an expanded arrangement with Rigel Pharmaceuticals, Inc, effective October 14, 2024, to include commercial distribution of TAVALISSE® (fostamatinib). TAVALISSE is an oral medicine that can help patients manage chronic immune thrombocytopenia (ITP) by protecting their platelets from destruction.
